World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
57018
World Ranking
11493
National Ranking
354

Overview

Francois Guilhot is affiliated with Grenoble Alpes University in France, focusing their research primarily in the field of Medicine, with a substantial subset of work in Hematology, Genetics, Rheumatology, Oncology, and Molecular Biology. Their scholarly output reflects a strong emphasis on hematological disorders and related therapeutic approaches.

Their research addresses several main topics, including:

  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Eosinophilic Disorders and Syndromes
  • CAR-T cell therapy research
  • Monoclonal and Polyclonal Antibodies Research
  • Protein purification and stability
  • Economic and Financial Impacts of Cancer

Francois Guilhot has contributed to numerous publications, with notable recent papers including:

  • "European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia" (2020, Leukemia)
  • "The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia" (2020, Leukemia)
  • "Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients" (2021, British Journal of Haematology)
  • "Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML" (2020, Cancer Research)
  • "European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission" (2024, Journal of Clinical Oncology)

Their frequent co-authors include Delphine Réa, François-Xavier Mahon, Joëlle Guilhot, Andreas Hochhaus, and Susanne Saußele, signaling collaboration with researchers who have contributed significantly to hematology and oncology fields.

Francois Guilhot's work is published frequently in several key scientific venues, among which the most frequent are:

  • Bulletin de l Académie Nationale de Médecine
  • Leukemia
  • British Journal of Haematology
  • Cancer
  • Blood

Best Publications

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

    François-Xavier Mahon;Delphine Réa;Joëlle Guilhot;François Guilhot

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

    Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman

  • Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

    Michel Attal;Jean-Luc Harousseau;Thierry Facon;François Guilhot

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Andreas Hochhaus;Richard A. Larson;François Guilhot;Jerald P. Radich

  • Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

    A. Hochhaus;S. G. O'Brien;F. Guilhot;B. J. Druker

  • International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib

    Michael Deininger;Stephen G O'Brien;François Guilhot;John M Goldman

  • Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

    Richard A. Larson;Brian J. Druker;Francois A. Guilhot;Stephen G. O'Brien

  • Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia

    Guilhot F;Chastang C;Michallet M;Guerci A

  • Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial

    Philippe Moreau;Thierry Facon;Michel Attal;Cyrille Hulin

  • Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

    Timothy P. Hughes;Andreas Hochhaus;Susan Branford;Martin C. Müller

  • Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

    Joerg Hasford;Michele Baccarani;Verena Hoffmann;Joelle Guilhot

Frequent Co-Authors

Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Jorge E. Cortes
Jorge E. Cortes Augusta University
Michele Baccarani
Michele Baccarani University of Bologna
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Michael W. Deininger
Michael W. Deininger University of Utah
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Neil P. Shah
Neil P. Shah University of California, San Francisco
Richard A. Larson
Richard A. Larson University of Chicago
Brian J. Druker
Brian J. Druker Oregon Health & Science University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative and complementary career pathways in healthcare is easier than ever with a range of online degrees tailored to medicine and allied fields. For those interested in healthcare leadership and management, choosing an affordable mha online program can be a cost-effective way to advance your career while continuing to work.

Nursing professionals may consider the best online bsn to dnp programs, which offer a direct pathway to top clinical and executive roles. Meanwhile, prospective pharmacists can benefit from enrolling in a pharmacy degree online, opening doors to specialized and in-demand pharmacy careers.

As the role of technology in medicine grows, earning credentials from healthcare informatics degree programs can be valuable for those interested in health information management or data analytics. These online programs allow flexibility, accessibility, and affordability for individuals seeking to build a future in healthcare beyond traditional medical school.

Best Scientists Citing Francois Guilhot

Trending Scientists

Recently Published Articles